Contributions to Skin Care Research, Financial Results, FDA Clearances, and Strategic Acquisitions - Research Report on Nu Skin, PVH, Kimberly-Clark, Unilever, and Quiksilver

NEW YORK, September 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Nu Skin Enterprises Inc. (NYSE: NUS), PVH Corp. (NYSE: PVH), Kimberly-Clark Corporation (NYSE: KMB), Unilever NV (NYSE: UN), and Quiksilver Inc. (NYSE: ZQK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Nu Skin Enterprises Inc. Research Report

On September 9, 2013, Nu Skin Enterprises Inc. (Nu Skin) announced that it continues to contribute to the body of scientific skin care research on the aging process by presenting two scientific posters at the International Investigative Dermatology (IID), speaking at the HBA Global Expo and publishing an article in the June 2013 issue of Euro Cosmetics. "It is an honor to have been invited to participate at such prestigious events throughout the world and be able to share with the scientific community our research findings," said Dr. Helen Knaggs, Ph.D, Vice President of Research and Development for Nu Skin personal care. "Gaining further insights into the role that our genes play in the aging process and continuing to develop anti-aging solutions will help us to continually refresh the vibrancy of the opportunity and products we offer." The Full Research Report on Nu Skin Enterprises Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4acf_NUS]

--

PVH Corp. Research Report

On September 9, 2013, PVH Corp. (PVH) reported its Q2 FY 2013 financial results (period ended August 4, 2013). The Company reported revenue growth of 47.0% YoY to c.$2.0 billion. According to the Company, the increase was driven by the addition of approximately $507 million of revenue associated with the Company's acquisition of The Warnaco Group, Inc. Non-GAAP EPS totaled $1.39 during the quarter, which exceeded the Company's guidance of $1.35 and Q2 FY 2012 EPS of $1.28. GAAP loss per share for the quarter was $0.20 per share, compared to earnings of $1.22 per share in Q2 FY 2012. Further, for full-year FY 2013, PVH expects revenue on a non-GAAP basis to be c.$8.3 billion. The Full Research Report on PVH Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fbc7s_PVH]

--

Kimberly-Clark Corporation Research Report

On September 5, 2013, Kimberly-Clark Corp. (Kimberly-Clark) announced that it has received U.S. Food and Drug Administration (FDA) clearance for use of its KIMGUARD ONE-STEP Sterilization Wrap portfolio with all Advanced Sterilization Products (ASP) STERRAD Systems, including the new DUO Cycle for the STERRAD 100NX System. The Company reported that it is the first and only manufacturer to receive the 510(k) clearance from FDA for the product. Steve Camp, Vice President, Regulatory and Clinical Affairs, Kimberly-Clark Health Care said, "Thorough testing and evaluation of the KIMGUARD family of Sterilization Wrap products with all available sterilization processing modalities are paramount to sterility assurance. Kimberly-Clark is pleased to provide clinicians with this added assurance of sterility of their instruments supporting their mission of delivering excellent patient care." The Full Research Report on Kimberly-Clark Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a3ff_KMB]

--

Unilever NV Research Report

On September 6, 2013, Unilever NV (Unilever) announced that it has entered into a definitive agreement to acquire T2, an Australian tea business for an undisclosed amount. Kevin Havelock, Unilever President for Refreshment said, "T2 is a fast growing premium tea business with great potential. This will allow us to bring the benefits of scale and access to new markets to the T2 business and for both businesses to share tea category expertise. This deal will also bring a premium tea business to complement our portfolio that we can leverage in a similar way to other recent Unilever acquisitions." The Full Research Report on Unilever NV - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/003f_UN]

--

Quiksilver Inc. Research Report

On September 5, 2013, Quiksilver Inc. (Quiksilver) reported its Q3 FY 2013 financial results (period ended July 31, 2013). The Company reported net revenues of $496 million compared with $512 million in Q3 FY 2012. Net income attributable to Quicksilver totaled $2 million or $0.01 per diluted share, compared with $13 million or $0.07 per diluted share reported in Q3 FY 2012. "Our third quarter results reflect progress on our path toward improving operating efficiencies," said Andy Mooney, President and CEO of Quiksilver, Inc. "While global net revenues were down for our DC and Quiksilver brands, we believe that the product development plans we have in place will deliver improved sales over time." The Full Research Report on Quiksilver Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c606_ZQK]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner